Thymectomy has become an increasingly popular procedure for myasthenia gravis. Knowledge of factors associated with a good outcome (remission) or those most likely to benefit from surgery can help clinical decision-making. A systematic review search was conducted in Medline and Embase for English language studies from 1985 through to February 2014. Studies which evaluated variables associated with, or predictive of, remission in adult (≥18 years) myasthenic patients after thymectomy and using multivariable regression models were included. Statistical pooling was not appropriate due to methodological heterogeneity. From 128 potentially relevant studies, 18 reports of 19 studies met the inclusion criteria. Preoperative mild disease classification (i.e. studies reported this variable as Osserman classification 1, 2A or MGFA I-II) showed the most consistent association with remission. Evidence for several other prognostic factors was inconclusive, or no evidence was found. Gender, age and absence of thymoma (or hyperplasia) were not associated with remission following thymectomy. Patients with mild disease preoperatively may have a better chance of remission of MG after thymectomy.
INTRODUCTION
Myasthenia gravis (MG) is a relatively rare autoimmune neuromuscular disorder, characterized by the production of abnormal autoantibodies directed against nicotinic acetylcholine receptors in neuromuscular junctions by the thymus gland. The clinical hallmarks of MG are weakness and fatigability of skeletal and extraocular muscles. The clinical course of MG is variable, ranging from remission in an early stage to an acute exacerbation and even death. Over the past few decades, prognosis has been dramatically improved, mainly owing to advances in pharmacological development and thymectomy [1] . Spontaneous remission is uncommon. Guidelines and recommendations suggest that thymectomy is valuable as a form of treatment of MG [2] . We do not know which patient factors are associated with remission following thymectomy.
Identification of the prognostic factors associated with remission after thymectomy will help optimize patient selection for this procedure, which in turn may reduce health-care costs and avoid exposing patients to unnecessary procedures and related complications. We performed a systematic review of the literature to determine patient factors associated with remission of MG after thymectomy as part of our continuing research into the course and prognosis of MG [3] .
METHODS
This systematic review was undertaken following PRISMA guidelines [4] .
Search strategy
We searched Medline, Web of science and Embase databases to retrieve relevant studies published between January 1985 and February 2014. We used the following key words and medical subject headings: myasthenia gravis, thymectomy, remission, prognos*(truncated), predict* (truncated). We also reviewed the references of the identified articles.
Study selection
Two reviewers (Zhifeng Mao and Xueqiang Hu) screened the titles and abstracts of all identified articles for eligibility. An article was eligible if it met all the following criteria: (i) publication in English; (ii) the study population consisted of adults ≥18 years of age (wholly or predominantly); (iii) one of the aims of the study was to assess the variables associated with, or predictive of, the outcome of MG after thymectomy; (iv) the outcome included remission [according to definitions of the Myasthenia Gravis Foundation of America (MGFA)] [5] ; (v) follow-up was ≥6 months after surgery and (vi) multivariable regression was used to determine variables associated with remission of MG. Studies published before the MGFA recommendations, which measured remission in a similar fashion to the guideline criteria, were also included. Articles were deemed ineligible if they met any of the following criteria: (i) reports were of mixed populations, unless separate results for MG patients were identified; (ii) studies included patients who had not undergone thymectomy unless separate results for patients post-surgery were available; (iii) studies in which minimal manifestations and/or improvement was part of a composite end-point [5] . We included studies of thymomatous MG and non-thymomatous MG to enable consideration of clinical decision-making for these specific subgroups. Decisions about the inclusion of studies were made independently, and any disagreements were resolved through consensus or by arbitration of a third person (Zhengqi Lu).
Data extraction
Studies were stratified based on the following three categories that represented degrees of case selection: (i) Patients included thymoma and non-thymoma (global patients); (ii) patients without thymoma; (iii) patients with thymoma. Zhifeng Mao extracted the following information [6, 7] : clinical details (country, period of enrolment, sample size, age, sex); MG subtypes (ocular, severity, with thymoma); study design (in particular, if retrospective or prospective, if inclusion and exclusion criteria were defined, if inclusion was consecutive, if this was an inception cohort, if baseline data were provided); follow-up (time since thymectomy and patients lost to follow-up); outcome measure [complete stable remission (CSR) or those definitions equal to CSR: no symptoms or signs of MG for at least 1 year without medication during that time [5] ]; statistical analysis and quality (type of regression model, Cox or logistic); and if events per variable ratio is sufficient; reported P-value, odds ratio or hazard ratio, 95% confidence interval (CI), β-regression and/or standard error (SE), Kaplan-Meier analysis/survival analysis, percent in remission reported at each assessment; and prognostic factors included in univariate and multivariate analysis and number of variables with independent prognostic value in the multivariate model. To maximize homogeneity of the study group, the primary analyses examined the studies including patients not specific to thymomatous or non-thymomatous MG.
RESULTS

Search results
Our search performed on 20 February 2014, identified 128 articles ( Fig. 1 ). Of these, 71 were excluded on the basis of title or abstract and 57 reports were identified for full-text review. Two additional reports were identified by searching relevant reference lists. Of the 59 reports that were reviewed in full text, 18 reports of 19 studies were included in this review [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Study characteristics
The characteristics of the included studies are summarized in Table 1 . The agreement between reviewers for inclusion of articles was 99.4%, with a kappa of 0.81 (95% CI 0.70-0.90; almost perfect agreement) [27] . Investigators recruited patients over several years, and most studies were conducted in Europe and Asia. The number of included patients ranged from 27 to 962. Patients' mean or median ages varied from 25 to 56 years, and there was a predominance of females in most studies. Several surgical approaches were used. The most frequent approach was extended transcervical thymectomy and the second was videoscopic-assisted thymectomy: VATET (bilateral). Two or more approaches were used in six studies [13, 15, 16, 21, 24, 26] .
Clinical details, design and statistical analysis
The MG patients enrolled across studies were very heterogeneous and only 9 studies included patients at different clinical stages of MG (global patients) [9] [10] [11] [12] [13] [14] [15] [16] [17] . Six cohorts included only nonthymomatous [18] [19] [20] [21] [22] [23] and four cohorts included only thymomatous patients [22] [23] [24] [25] [26] 28] ; one study included patients with only 
Follow [8] . All the studies used retrospective recruitment methods and only a minority (32%) included consecutive patients.
Although not specified in all study reports, only one study included an inception cohort (≤3 years from the onset of symptoms or the appearance of the first sign of disease). In 15 included studies, Cox proportional-hazard modelling was used to determine the time to remission and report hazard ratios, i.e. the relative effect of a prediction factor on an outcome, assuming that this relation is constant over time. Three studies used the less appropriate 'logistic regression', which focuses only on the occurrence (or not) of the event, regardless of time, and is expressed as an odds ratio. The statistical quality and presentation of methods and results were suboptimal in many studies. Although regression was performed in all studies, the events per variable ratio were insufficient in three studies, and three studies reported an inexact estimate of probability, i.e. P < 0.05. Other methodological problems included not providing β-regression coefficients and/or SE (80%), no description of hazard ratio or odds ratio (47%) and Kaplan-Meier analysis/survival analysis in study (33%).
Follow-up duration and remission in prognostic studies
The mean length of follow-up after thymectomy varied from 26.5 months to 15 years (Table 1) . Two studies reported only the maximal duration of follow-up. Reported loss to follow-up varied from 0 to 35%. Of the studies included in our review, 74% defined remission according to the MGFA postintervention status. Some studies defined remission as the absence of MG symptoms or signs for at least 6 months instead of 1 year, or simply the absence of symptoms without specifying a time period. In 55% of studies, estimates of the remisssion rate of MG were provided. Overall, the CSR rate varied from 9.6 to 57.5% (Table 1 ). Figure 2 illustrates that the CSR rate of patients was positively correlated with the time since thymectomy.
Prognostic variables
Many variables [demographic (19 studies), clinical (19 studies), thymus pathology (19 studies), pre/postoperative treatment (13 studies), variables related to surgery (7 studies) and laboratory testing (5 studies)] were considered for association with remission post-thymectomy (see Tables 1 and 2 ). The mean number of variables that were independently predictive of remission in these 19 studies was 2 (range 0-5). A total of 32 different variables were assessed across the studies, although only 8 variables (25%) were assessed in ≥5 studies. Of those, only mild preoperative severity of disease (i.e. studies reported this variable as Osserman classification 1, 2A or MGFA I-II) showed the most consistently positive association with remission (6 of 8; i.e. a significant association in 6 of 8 studies which assessed this variable). Among the other variables considered, female sex showed no association (18/18, i.e. no association in 18 of 18 studies). Furthermore, no association was found between early age of onset (7 of 9) and absence of thymoma (or hyperplasia) (7 of 9). Finally, no association was found in groups of thymomatous-MG and non-thymomatous-MG currently.
DISCUSSION
As far as we know, this paper is the first reported systematic review of prognostic factors for MG outcome after thymectomy. During this systematic review, we identified 18 relevant articles that showed diversity in the study population (i.e. inclusion of patients at different disease stages and subtypes); in the prognostic variables included in the analysis; in the type of statistical analyses applied in the studies; and in the definition used for remission and other variables. These variations may have resulted in selection bias, low statistical power and limited opportunity to integrate results. In addition, the quality of the studies included was heterogeneous and usually suboptimal. Firstly, it is necessary to consider that all the evidence in this review came from studies with retrospective recruitment. Since retrospective recruitment is prone to selection bias and the strength of the evidence from retrospective studies is considered lower than that provided from prospective studies, these findings should be interpreted with caution. Secondly, we note that only two (range 0-5) independent predictors were identified on average. Some studies included in their multivariate analysis only those variables that were statistically significant after univariate analysis. This reduces the number of variables in the multivariable model, which is necessary owing to the small number of cases in most studies. However, a non-significant association in a univariate analysis may change the overall model if the same variable is controlled for in the multivariate analysis. Thirdly, many studies in this review failed to use guideline-based definitions of remission [5] . It should be noted that remission is a time-dependent variable and reported remission rates could be biased in studies using a 6-month cut-off point rather than 1 year [13] . Fourthly, the included studies had different followup periods. We suggest that some prognostic factors might be different for short-and long-term recovery. However, the absence of a detailed definition on cut-off points prevents examination of prognostic factors over a narrow range of follow-up durations.
There was a wide range in the reported proportion in remission (from 9.6 to 57.5%) at the end of follow-up across the studies. This may be explained by the heterogeneity of the included study participants as patients were included at different stages of MG (Fig. 2) . This emphasizes the importance of a clear description of the inception cohort in prognostic studies and the use of standardized methods. In addition, details of postoperative medication were seldom reported. It should be noted that adequate evidence for the effect of thymectomy is lacking as there has not been a randomized study. Even low-dose prednisone treatment after [13, 29] . Thus, it is possible that the treatment effect of thymectomy might be a combined treatment effect and, consequently, result in a different remission rate. Despite these limitations and methodological caveats, this systematic review allowed the identification of the most consistent predictors of remission in MG after thymectomy. Firstly, mild disease severity seems to be associated with remission after surgery. This highlights that early detection and surgical management of MG in the mild stages of disease could result in improved outcomes. Ocular MG was not uncommon (10, 21 and 33%) [11, 12, 17] and it is reasonable to assume that some authors have advocated surgery for patients with purely ocular MG, particularly when the symptoms are disabling and poorly controlled by medical therapy. As the absence of thymoma or hyperplasia did not influence postoperative remission, thymic pathology should not influence the indication for thymectomy. An international clinical prospective study (MGTX study) that may shed light on this issue is being conducted and due to be completed by the end of 2015 [30] .
In conclusion, a better understanding of prognostic factors in MG after thymectomy has evolved over recent decades. Despite the acknowledged difficulties in the assessment of outcome of chronic and rare diseases with unpredictable and fluctuating courses, we present evidence of a possible increase in the chance of remission of MG after thymectomy for a subgroup of patients with preoperative mild disease.
